ANAVEX2-73 Study in Patients With Rett Syndrome (AVATAR)
A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This Phase 3 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study.
This is a 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients to continue a 48-week open label extension.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Greenwich, New South Wales, Australia, 2065
- HammondCare
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Mater Misericordiae Ltd
-
-
Victoria
-
Melbourne, Victoria, Australia, 3181
- The Alfred Hospital
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital (RMH)
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- The Keogh Institute for Medical Research
-
-
-
-
UK
-
London, UK, United Kingdom, SE5 8AF
- King's College of London
-
Manchester, UK, United Kingdom, M13 9WL
- Manchester CGM, St. Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥ 18 years, inclusive.
- Diagnosis of classic RTT, according to 2010 criteria (Neul et al., 2010), and a MECP2 mutation.
- Current pharmacological treatment regimen, including supplements, has been stable for at least 4 weeks.
- If on antiepileptic drugs (AEDs), 1-4 AEDs allowed. Treatment must be stable (drug, dose, interval of administration) for 30 days prior to enrollment.
- If the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 90 days prior to the screening visit and subjects or their parent/caregiver/legally authorized representative (LAR) will not electively initiate new or modify ongoing interventions for the duration of the study. 'Study duration' is defined as lasting from the screening visit until the treatment is terminated. For participants in the 16-21 years range, typical school vacations are not considered modifications of stable programming.
- Ability to keep accurate seizure diaries or have caregiver who can keep accurate seizure diaries.
- Confirmation from the participant that, if of childbearing potential is not pregnant through urine pregnancy testing. Female patients of childbearing potential and at risk for pregnancy must agree to abstinence.
- Prior to the conduct of study-specific procedures, the subject's parent/caregiver/LAR must provide written informed consent. If applicable, the research team
Exclusion Criteria:
- Patients who have a progressive medical or neurological condition that in the opinion of the Investigator would interfere with the conduct of the study.
- Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
- History of clinically evident stroke or clinically significant carotid or vertebrobasilar stenosis or plaque or other history of neurologic (e.g., head trauma with loss of consciousness) or psychiatric condition that the Investigator deems may interfere with interpretability of data.
- Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal (ULN) as determined during screening.
- Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
- Other clinically significant abnormality on physical, neurological, laboratory, or electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise the study or be detrimental to the participant.
- Any known hypersensitivity to any of the excipients contained in the study drug or placebo formulation.
- Other co-morbid or chronic illness beyond that known to be associated with RTT.
- Subjects who plan to initiate or change pharmacologic or nonpharmacologic intervention during the course of the study.
- Subjects taking another investigational drug currently or within the last 30 days.
- Any other criteria (such as a clinically significant screening blood test result), which in the opinion of the Investigator could interfere with the study conduct or outcome.
- Subjects on potent CYP3A4 and CYP2C19 inhibitors and inducers.
- Patients with hepatic and renal impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active arm
ANAVEX2-73 liquid oral solution
|
Liquid oral solution
|
|
Placebo Comparator: Placebo arm
Placebo liquid oral solution
|
Liquid oral solution
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RSBQ
Time Frame: 7 weeks
|
Drug exposure-dependent response of the Rett Syndrome Behaviour Questionnaire (RSBQ) Total score
|
7 weeks
|
|
Incidence of Adverse Events
Time Frame: 7 weeks
|
Incidence of Adverse Events
|
7 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CGI-I
Time Frame: 7 weeks
|
Drug exposure-dependent response of the Clinical Global Impression of Improvement Scale (CGI-I) score
|
7 weeks
|
|
Anxiety, Depression, and Mood Scale (ADAMS)
Time Frame: 7 weeks
|
Drug exposure-dependent response of the Anxiety, Depression, and Mood Scale (ADAMS)
|
7 weeks
|
|
Maximum Plasma Concentration [Cmax] of ANAVEX2-73
Time Frame: 7 weeks
|
PK of ANAVEX2-73 and metabolite
|
7 weeks
|
|
Area Under the Curve [AUC] of ANAVEX2-73
Time Frame: 7 weeks
|
PK of ANAVEX2-73 and metabolite
|
7 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Children's Sleep Habits Questionnaire (CSHQ)
Time Frame: 7 weeks
|
Children's Sleep Habits Questionnaire (CSHQ)
|
7 weeks
|
|
Seizure Frequency via seizure diary
Time Frame: 7 weeks
|
Seizure Frequency via seizure diary
|
7 weeks
|
|
Genetic variant SIGMAR1, COMT
Time Frame: 7 weeks
|
Genetic variant SIGMAR1, COMT
|
7 weeks
|
|
Glutamate Plasma Concentration
Time Frame: 7 weeks
|
Glutamate Plasma Concentration
|
7 weeks
|
|
GABA Plasma Concentration
Time Frame: 7 weeks
|
GABA Plasma Concentration
|
7 weeks
|
|
Lipid panel
Time Frame: 7 weeks
|
Significant laboratory findings
|
7 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANAVEX2-73-RS-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.